Bausch & Lomb Corp (BLCO) Stock Price, Quote & News

Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeut...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 905-695-7700

Website: www.bausch.com

Address:

520 Applewood Crescent, Vaughan, Canada

MetricsMyth Dec. 27 at 2:30 PM

$BLCO Investors are weighing durability against tactical noise; free‑cash‑flow conversion needs to normalize — stable fundamentals would matter more than macro swings. Markets will follow data, not narratives.

0 · Reply

Axonius300 Dec. 22 at 2:06 AM

$BLCO If they get bought out, the buyer will regret it. They'd get 20 billion of debt, incompetant leadership and copycat products. Such a shame what the executives have done to this company.

0 · Reply

egolden08 Dec. 16 at 7:41 PM

$BLCO Disregard 😂

0 · Reply

egolden08 Dec. 16 at 7:34 PM

$BLCO I’m watching Bloomberg and the headline “Icahn Sues Bausch and Lomb for Anti-White…” flashes accross one of the little infomation banners. I haven’t seen any other evidence of this 🤷‍♂️ weird…

1 · Reply

LeaverTrades Dec. 16 at 2:28 PM

$BLCO looks like it might make a move higher on the shorter term (30m) timeframe. Though - it seems we might be up against a previous level of resistance on the weekly timeframe. Considering it's run 10-17$ on the daily - does it have enough energy to push through? Something to think about.

0 · Reply

kbingo12 Dec. 11 at 1:30 PM

$BLCO → Buy at Citi; PT 20

0 · Reply

BillionerOfKing Dec. 6 at 1:20 AM

$BLCO Current Stock Price: $16.83 Contracts to trade: $20 BLCO Dec 19 2025 Call Entry: $0.14 Exit: $0.20 ROI: 49% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Contrarian_Dan Dec. 2 at 8:46 PM

$BLCO Is a buy offer coming?

0 · Reply

JarvisFlow Dec. 2 at 5:26 PM

Morgan Stanley has updated their rating for Bausch & Lomb ( $BLCO ) to Overweight with a price target of 21.

0 · Reply

notreload_ai Dec. 2 at 12:00 PM

Morgan Stanley updates ratings for $INSP , $DXCM , and $BLCO , highlighting slowing growth, improving operations, and strong long-term pipelines. https://notreload.xyz/morgan-stanley-updates-ratings-on-insp-dxcm-blco/

0 · Reply

Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 4:30 PM EST - 10 days ago

Bausch + Lomb Announces Two Board of Directors Appointments

Dec 12, 2025, 4:48 PM EST - 15 days ago

Bausch + Lomb Announces Refinancing of Outstanding Term B Loans

Dec 3, 2025, 12:43 PM EST - 24 days ago

Bausch + Lomb Corporation (BLCO) Bausch + Lomb Corporation Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 18, 2025, 4:30 PM EST - 5 weeks ago

Bausch + Lomb to Participate in Citi Global Healthcare Conference

Nov 17, 2025, 7:57 PM EST - 5 weeks ago

Bausch + Lomb Corporation (BLCO) Bausch + Lomb Corporation - Analyst/Investor Day Transcript

Nov 10, 2025, 6:59 AM EST - 6 weeks ago

Bausch + Lomb Reports More Than 690,000 Pounds of Contacts Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE Recycling Program

Oct 29, 2025, 2:26 PM EDT - 2 months ago

Bausch + Lomb Corporation (BLCO) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 6:58 AM EDT - 2 months ago

Bausch + Lomb Announces Third-Quarter 2025 Results

Oct 19, 2025, 8:00 PM EDT - 2 months ago

Activist Jana Takes Stake in Cooper, a Maker of Medical Devices

COO

Sep 29, 2025, 7:15 AM EDT - 3 months ago

Bausch + Lomb Will Release Third-Quarter 2025 Financial Results on Oct. 29 and Hold Investor Day on Nov. 13

Sep 8, 2025, 2:37 PM EDT - 3 months ago

Bausch + Lomb Corporation (BLCO) Bausch + Lomb Corporation Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 7:00 AM EDT - 3 months ago

Bausch + Lomb Launches ASANA™ Gas Permeable Lenses in the United States

Aug 18, 2025, 5:01 PM EDT - 4 months ago

Bausch + Lomb Announces Board Changes

Aug 14, 2025, 7:15 AM EDT - 4 months ago

Bausch + Lomb to Participate in Upcoming Investor Conferences

Jul 30, 2025, 9:33 PM EDT - 5 months ago

Bausch + Lomb Corporation (BLCO) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 6:57 AM EDT - 5 months ago

Bausch + Lomb Announces Second-Quarter 2025 Results

Jul 1, 2025, 7:00 AM EDT - 6 months ago

Bausch + Lomb Combines Patient Voices and New Survey Insights to Combat Persistent Misconceptions about Dry Eye

Jun 30, 2025, 6:58 AM EDT - 6 months ago

Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13

Jun 18, 2025, 4:30 PM EDT - 6 months ago

Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering

Jun 17, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Bausch + Lomb Corporation (BLCO) And Encourages Investors to Connect

Jun 16, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Bausch + Lomb Corporation (BLCO) Stockholders to Inquire about Securities Investigation

Jun 15, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bausch + Lomb Corporation (BLCO) and Encourages Investors to Learn More About the Investigation

Jun 13, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bausch + Lomb Corporation (BLCO) And Encourages Investors to Reach Out

Jun 12, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bausch + Lomb Corporation (BLCO) And Encourages Stockholders to Reach Out

Jun 11, 2025, 10:02 AM EDT - 7 months ago

BLCO Investors Have Opportunity to Join Bausch + Lomb Corporation Fraud Investigation with the Schall Law Firm

Jun 11, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Bausch + Lomb Corporation (BLCO) And Encourages Stockholders to Connect

Jun 10, 2025, 10:00 AM EDT - 7 months ago

Bausch + Lomb Corporation (BLCO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jun 10, 2025, 8:48 AM EDT - 7 months ago

Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement

Jun 9, 2025, 12:00 PM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bausch + Lomb Corporation (BLCO) and Encourages Stockholders to Learn More About the Investigation

May 22, 2025, 7:30 AM EDT - 7 months ago

Bausch + Lomb to Participate in the 2025 Jefferies Global Healthcare Conference

May 21, 2025, 4:30 PM EDT - 7 months ago

Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results

Apr 30, 2025, 11:02 AM EDT - 8 months ago

Bausch + Lomb Corporation (BLCO) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 6:57 AM EDT - 8 months ago

Bausch + Lomb Announces First-Quarter 2025 Results

Apr 24, 2025, 7:00 AM EDT - 8 months ago

Bausch + Lomb Returning enVista® Intraocular Lenses to Market Following Voluntary Recall

Apr 11, 2025, 10:00 AM EDT - 9 months ago

Bausch + Lomb (BLCO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 10, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Bausch + Lomb (BLCO) Shareholders to Inquire about Securities Investigation

Apr 9, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Bausch + Lomb (BLCO) And Encourages Shareholders to Connect

Apr 8, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bausch + Lomb (BLCO) And Encourages Shareholders to Reach Out

Apr 7, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bausch + Lomb (BLCO) and Encourages Investors to Learn More About the Investigation

Apr 6, 2025, 10:00 AM EDT - 9 months ago

Bausch + Lomb (BLCO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Apr 4, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Bausch + Lomb (BLCO) And Encourages Investors to Connect

Apr 3, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Bausch + Lomb (BLCO) Stockholders to Inquire about Securities Investigation

Apr 2, 2025, 10:00 AM EDT - 9 months ago

Bausch + Lomb (BLCO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Apr 1, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bausch + Lomb (BLCO) and Encourages Stockholders to Learn More About the Investigation

MetricsMyth Dec. 27 at 2:30 PM

0 · Reply

Axonius300 Dec. 22 at 2:06 AM

$BLCO If they get bought out, the buyer will regret it. They'd get 20 billion of debt, incompetant leadership and copycat products. Such a shame what the executives have done to this company.

0 · Reply

egolden08 Dec. 16 at 7:41 PM

$BLCO Disregard 😂

0 · Reply

egolden08 Dec. 16 at 7:34 PM

1 · Reply

LeaverTrades Dec. 16 at 2:28 PM

0 · Reply

kbingo12 Dec. 11 at 1:30 PM

$BLCO → Buy at Citi; PT 20

0 · Reply

BillionerOfKing Dec. 6 at 1:20 AM

0 · Reply

Contrarian_Dan Dec. 2 at 8:46 PM

$BLCO Is a buy offer coming?

0 · Reply

JarvisFlow Dec. 2 at 5:26 PM

Morgan Stanley has updated their rating for Bausch & Lomb ( $BLCO ) to Overweight with a price target of 21.

0 · Reply

notreload_ai Dec. 2 at 12:00 PM

0 · Reply

Stock_Spectator Nov. 21 at 6:51 PM

$BHC $BLCO following $COO activist saga? I’d take a takeover or strategic partnership.

0 · Reply

JarvisFlow Nov. 14 at 3:40 PM

RBC Capital has adjusted their stance on Bausch & Lomb ( $BLCO ), setting the rating to Outperform with a target price of 17 → 19.

0 · Reply

JarvisFlow Nov. 14 at 3:15 PM

Wells Fargo has adjusted their stance on Bausch & Lomb ( $BLCO ), setting the rating to Equal-Weight with a target price of 16 → 17.

0 · Reply

theoptionsplug Nov. 13 at 6:23 AM

📊Earnings + Implied Moves: Applied Materials $AMAT (~5.58%), Disney $DIS (~6.82%), JD .com $JD (~6.18%), and StubHub $STUB (~21.64%) 💼CNBC hosts its Delivering Alpha Conference, featuring speakers such as Ares Management CEO and Co-founder Michael Arougheti. 🛢️The IEA releases its monthly oil market report. 👁️8:00AM: San Francisco Fed President Mary Daly speaks. 📈8:30AM: Initial Jobless Claims and the Consumer Price Index (CPI) data are scheduled for release. 💬9:20AM: New York Fed President John Williams delivers welcoming remarks. 🧾8:30AM: Bausch & Lomb $BLCO holds its investor day. 💪10:00AM: Planet Fitness hosts its investor day. 🏦10:25AM: Minneapolis Fed President Neel Kashkari delivers opening remarks. 🏛️12:15PM: St. Louis Fed President Alberto Musalem speaks at the Evansville Regional Economic Partnership’s Economic Impact and Policy Forum. 💬12:20PM: Cleveland Fed President Beth Hammack speaks. Continued in replies***

1 · Reply

algomezus Nov. 12 at 5:53 PM

$BLCO $BHC let go BLCO my estranged offspring get to 17.

0 · Reply

quegoalasoche Nov. 11 at 12:04 PM

$BLCO based off charts, short to 14 pop to 20.

0 · Reply

aaxaa Nov. 10 at 4:22 PM

$BLCO $INCY twinning?

1 · Reply

vcd103 Oct. 26 at 1:08 AM

$BHC $BLCO RBC had this interesting comment on potential sale timing.. RBC Capital has reiterated its Market Perform rating and US$10 price target on Bausch Health Companies (BHC.NaE) ahead of its third-quarter results. Analyst Douglas Miehm estimates third quarter revenue of US$2.65 billion (vs. cons. US$2.62 billion). Key areas of focus include updates on the ongoing Xifaxan patent litigation and potential policy-related headwinds, Miehm notes. "Additionally, we will look for commentary on management's strategic vision for the BLCO asset. In our view, should a sale of the asset materialize, it would most likely occur in the 2026/2027 time frame."

1 · Reply

CindyH0o Oct. 24 at 7:27 AM

$BHC jaw dropping. J. Paulson latest filing of BHC ownership. $BLCO

2 · Reply

ChubbRock999 Oct. 22 at 11:57 AM

$BHC if $COO and $BLCO were to merge, would BHC have to approve it?

1 · Reply

smartoptionstrader Oct. 20 at 6:14 PM

ACTIVIST ALERT: Jana Partners took a stake in $COO demanding a breakup or merger with $BLCO. Stock popped 6%+ but could be just the start. Jana has a 30% annual return track record forcing value-unlocking deals. Bausch + Lomb's CEO already endorsed the merger publicly—rare and bullish. $COO trades at $75 after holding critical support at $61.77, with technical resistance at $112-$116. Historical activist campaigns generate 30-50% premiums. Options traders positioning in 3-6 month calls as implied volatility spikes. Risk-reward heavily favors bulls here. Cooper Companies (COO) Monthly Chart from Barchart - Shows the bearish trend reversal at critical support ($61.77 near October 2022 low of $61.05), recent recovery to $75+, and technical resistance levels at September 2024 high ($112.38) and September 2021 record peak ($115.90). The chart illustrates the significant upside potential from current levels to previous highs.

0 · Reply

topstockalerts Oct. 20 at 12:41 PM

Cooper Cos. Stock Rises on Jana Partners' Activist Push Cooper Cos. saw its stock rise over 4% before market open on Monday after the Wall Street Journal reported that activist investor Jana Partners has built a stake in the company and plans to push for strategic alternatives, including potentially merging its contact lens unit with rival Bausch + Lomb. Jana believes the two business units of Cooper lack synergies and will advocate for changes to improve stock performance through better capital allocation and returns. The size of Jana's stake was not disclosed. The activist plan is already supported by Bausch + Lomb CEO Brent Saunders, who expressed interest in the potential merger in an interview. Cooper operates through two segments: CooperVision, a leading producer of soft contact lenses, and CooperSurgical, which provides women's health and fertility products and services. $COO $BLCO

0 · Reply

Market Cap	6.03B
Revenue (ttm)	4.79B
Net Income (ttm)	-317.00M
EPS (ttm)	N/A
PE Ratio	39.49
Forward PE	31.45
Profit Margin	-6.62%
Debt to Equity Ratio	0.76

Volume	175,400
Avg Vol	433,536
Day's Range	N/A - N/A
Shares Out	354.21M
Stochastic %K	75%
Beta	0.62
Analysts	Sell
Price Target	$17.23